Taplucainium chloride

Nocion Therapeutics presents data on preclinical and clinical development of Taplucainium, a novel, charged sodium channel blocker, as a potential treatment for chronic cough at the 13th London International Cough Symposium.
Taplucainium is a proprietary molecule in the novel class of charged sodium channel blockers that allows for specific silencing of activated/inflamed nociceptors while having minimal local off-target effects or systemic exposure. Unlike other investigative cough therapies, such as P2X3-antagonists, TRPA1-antagonists and TRPM8-agonists, which target a specific large pore channel, taplucainium works downstream by selectively targeting the sodium channels in activated nociceptors which are the target of these large pore channels.